Roche Holding AG
RO
Rangering i aksjer
#43
Roche Holding AG is a global healthcare enterprise with dual focuses:... Roche Holding AG is a global healthcare enterprise with dual focuses: pharmaceuticals and diagnostics. The company maintains a significant presence in numerous countries, including its home base in Switzerland, alongside Germany, the United States, Austria, the Netherlands, the United Kingdom, France, Belgium, and various other international markets. Its pharmaceutical segment develops and supplies treatments for a wide spectrum of medical conditions, encompassing oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments, as well as specific therapies for anemia, dermatology, hemophilia, inflammatory and autoimmune conditions, and transplant patients. On the diagnostic front, Roche provides in vitro tests designed to identify various diseases like cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, in addition to supplying crucial diagnostic instruments and reagents. The company was founded in Basel, Switzerland, in 1896.
Aksjekurs
$514.50
Markedsverdi
$349.98B
Endring (1 dag)
2.59%
Endring (1 år)
38.12%
Land
CH
Handel Roche Holding AG (RO)
Kategori
Healthcare
Inntekter for Roche Holding AG (RO)
Inntekter i Dec 2025 TTM: $21.39B
Ifølge Roche Holding AG sine nyeste økonomiske rapporter er selskapets nåværende resultat $21.39B. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Roche Holding AG fra 2026 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $33.60B | 57.07% |
US
|
|
| $17.74B | -17.07% |
US
|
|
| $8.70B | -59.33% |
US
|
|
| $5.95B | -72.19% |
US
|
|
| $16.38B | -23.42% |
CH
|
